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Abstract 
Female pattern hair loss (FPHL) is the most common hair loss in post-puberty female. Prevalence of this 
nonscarring alopecia increases with age.  The etiology of FPHL is still unclear, but hormonal and genetic factors 
are associated with pathogenesis of FPHL. Hormonal factor in FPHL is not as strong as in male pattern hair loss 
(MPHL). Clinical manifestations of FPHL are characterized by nonscarring baldness with shortening anagen 
phases and miniaturization of hair follicles, predominantly occur at the vertex, middle, and frontal regions. Hair 
shedding occurs progressively. The diagnosis of FPHL is established based on clinically. Classification of FPHL 
is according to Ludwig's criteria. Current FDA-approved FPHL therapy is topical minoxidil 2%, hair 
transplantation, and low level laser therapy (LLLT). Anti-androgen therapy still needs to be investigated further. 
The prognosis of FPHL is poor because the progressiveness continues with age. Long term treatment required 
for FPHL because it is a chronic residif disease. The treatment only prevents the progression of hair loss and 
does not cure. 
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Introduction 
Female pattern hair loss (FPHL) is a broad term for the decrease of hair density on 
cental scalp that affects post-puberty female. The other term that refer to FPFL are female 
androgenetic alopecia (AGA) and androgenic alopecia. Both term imply a specific androgen-
related and genetic predispotition.1 The role of androgen in FPHL is less clear than in male 
pattern hair loss (MPHL).2 It has not been prove that FPHL clearly has androgen-related 
process. 1,2 
Clinically, FPHL is noncicatricial pattern hair loss characterized by hair progressive 
thinning affecting mainly frontovertical region of the scalp.2 The epidemiology data of FPHL 
varies among population groups and ordinarily increase with age. Mostly, FPHL affects more 
than 50% female over the age of 50 years. Based on the onset of FPHL were classified in 
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early-onset (post-puberty to third decades) and late-onset (above 40 years old).1 About 40% of 
Caucasian female experienced FPHL by 70 years.2 
The main goal of management of FPHL is to arrest hair loss progression and stimulate 
hair regrowth.3 In early phase, topical minoxidil is recommended by Food and Drug 
Administration (FDA), but unresponsive case to minoxidil, finasteride, hair transplantation, 
low level laser therapy (LLLT), or/and hair piece can be an alternative.2,4 Several treatment 
modalities still need further investigation, such as microneedling and platelet rich plasma 
(PRP).5 
In this article, we review about the diagnosis and management of FPHL that may 
cause psychological distress and impaired social functioning for affected woman. Early 
diagnosis and adequate initiation of treatment are desirable. Avoiding the progression of hair 
loss would be more effective than stimulating regrowth. The treatment only prevents the 
progression of hair loss and does not cure. 
Etiopathogenesis 
The pathogenesis of FPHL is still remain unclear, FPHL is associated with androgen and 
genetic factors.1 However, not all cases of FPHL have elevated androgen hormone levels. In 
the hair follicle there are 5-α-reductase and aromatase enzymes that metabolize androgen 
hormones.1,6 5-α-reductase enzymes consist of 2 types namely I and II. (Figure 1) This 
enzyme functions to change testosterone to dihydrotestosterone (DHT) which has a 5 times 
greater affinity for hair androgen receptors responsible for gene transcription in target cells so 
that it can cause hair miniaturization.3 In addition, DHT interferes with the hair follicle cycle 
through the wingless type (Wnt). The Wnt pathway causes the dermal papilla to remain in the 
anagen phase. Some individuals with FPHL have low levels of sex hormone binding 
globuline (SHBG) thereby increasing the amount of free testosterone in hair follicles.6,7 
 Genetic factor on FPHL is still unclear.4 In women with FPHL, the incidence of hair 
loss in parents or siblings over 30 years old in men is 54% and in women is 21%.1  About 40-
54% family member of FPHL patient were affected, especially in early-onset cases.8 The 
strong evidence that shows gene involvement in man is the presence of androgen receptor 
gene (RA) polymorphisms located on the long arm of the X chromosome (Xq11-12). 
Polymorphisms in the first exon RA gene, known as Stul, are associated with baldness. The 
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RA gene contains the amino acid CAG on the first exon, variations in length and the amount 
of amino acid CAG on chromosomes are associated with the risk of baldness. The shorter the 
CAG repetition (<15) in gene transcription, the stronger the relationship with baldness, it is 
about 97.3%. However, there is less evidence of the role of AR gene in FPHL than in male 
pattern alopecia.6,9 
Clinical Manifestation and Classification 
The characteristics of FPHL are noncicatricial hair loss, with an increase in scalp hair 
miniaturization, thinning of the hair in the frontal, central, and parietal areas while the frontal 
hairline remains. This is due to the shortening of the anagen phase and the reduction in size of 
hair matrix.2,9 The pattern of baldness in FPHL is divided into 3 patterns: diffuse thinning of 
crown with preservation of the frontal hairline [3-point Ludwig scale and 5-point Sinclair 
scale], thinning and widening of the central part of the scalp with breach of frontal hairline 
that covers the superior part of the head but thinning hair widens on the frontal area to form a 
triangular area like a christmas tree (Olsen scale), and thinning associated with bitemporal 
recession, similar as baldness in male (Norwood-Hamilton scale).9,10,11 (Figure 1) 
 
 
 
 
 
 
 
Figure 1. FPHL pattern of baldness2 
 
The most widely used FPHL classification is the Ludwig (1977) classification. This 
classification is characterized by diffuse baldness on the area of the corona and the permanent 
frontal hairline. Ludwig divides FPHL into 3 point scale: grade I, thinning hair in the corona 
area, limited to 1-3 cm behind the frontal line; grade II, thinning hair is increasingly apparent 
in the area of grade I; grade III, total baldness in the area of grade I and II. (Figure 2) 
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    Grade I                  Grade II                 Grade III 
 
Figure 2. 3-point Ludwig scale for grading of FPHL1 
 
 
                 Grad 
 
Figure 3. 5-point Sinclair scale for grading of FPHL 6 
Examination and Diagnostic Tools 
Several examinations in FPHL such as clinical examination of skin and hair, as well as the 
nail, hair pull test, trichogram, trichoscopy, histopathology, and laboratory examination can be done to 
establish the diagnosis.2,9,12 Some diagnostic tools need to be done if the clinical diagnosis of FPHL is 
still uncertain or there are doubts about other diseases.2 
  Hair pull test (Sabouraud’s sign) is a noninvasive diagnostic technique that shows an increase 
in telogen hair release. To do a hair pull test, the patient should not clean hair with shampoo 24 hours 
before.10 The examination is done by grasping 50-60 hairs with thumb, index finger, middle finger 
from the base of the hair, then hair pulled slowly with the direction of the fingers following the hair 
shaft. The examination is carried out in the left and right parietal regions, frontal and occipital. 
Removal of six hairs indicates a positive pull test and active shedding.2 In FPHL, positive results if 
limited to the area affected during the active phase. If positive results occur in several regions of the 
head, a diagnosis of telogen effluvium is considered.10 
Grade I Grade II Grade III Grade IV Grade V 
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Trichogram is a semi-invasive examination technique by pulling hair using a needle holder 
and analyzing 50-100 hairs from the scalp under the light of a microscope. This check calculates the 
anagen: telogen hair ratio. In the early stages of FPHL, the trichogram shows a hair shaft that is not 
homogeneous.9,10 
Scalp tricoscopy or dermoscopy is a non-invasive diagnostic tool that is useful for diagnosing 
early-stage FPHL. Characteristics of FPHL on trichoscopy are differences in hair diameter or 
thickness > 20% with an increase in hair miniaturization, especially the frontoparietal region.10 At the 
initial stage of FPHL examination, peripillary markings, light brown areas, slightly atropic around 
follicles appear. This sign shows the relationship of inflammatory infiltrate on histopathological 
examination. In more severe cases, yellow dots are found (Figure 4). Dermoscopy has a specificity of 
98% .9 There are major and minor criteria for hair dermoscopy. The diagnosis of FPHL is made if it 
meets 2 major criteria or 1 major criteria and 2 minor criterias. In the major criteria found (1) more 
than 4 yellow dots in the frontal region, (2) differences in hair thickness in the frontal area: occipital 
less than normal, (3) in the frontal region> 10% thin hair (<0.03 mm). Minor criteria found (1) an 
increase in the ratio of single pilosebaceous units in the frontal: occipital region, (2) velus hair, (3) 
perifollicular discoloration.9,12 
 
 
Figure 4. Yellow dots in dermoscopy of FPHL patient. 
 
If hair loss occurs diffusely and does not on specific location, additional laboratory 
tests were required, thyroid stimulating hormone (TSH) and serum iron levels in patients with 
a history of iron deficiency, in diet, or a history of bleeding.6,13 Laboratory testing for 
androgens do not become routine. Serum androgen examination should be considered, 
especially in women with irregular menstruation, hirsutism, moderate-to-severe adult acne, 
and/or galactorrhea.14 At least, free/total testosterone with or without dehydroepiandrosterone 
sulfate (DHEA-S) examination should carried out in that case.2 
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Histopathological examination were needed when the diagnosis of FPHL is uncertain. 
Two biopsy punch 4 mm size from the middle area of hair baldness are taken following the 
hair shaft from lateral to midline to the subcutaneous fat tissue where the anagen hair bulb is 
located. Biopsy is not done in the temporal area because the hair follicles that shrink can be 
found in that area even though there is no FPHL. Vertical and horizontal biopsy pieces are 
parallel to the surface of the skin. Horizontal cuts can quickly assess the number of hair 
follicles, diameter, and morphology.10 Characteristics of the histopathological results are an 
increase in the number of miniaturization of hair follicles and progressive changes in terminal 
hair to velus hair. In FPHL, the ratio of terminal hair to velus hair is >3: 1, whereas in normal 
hair the ratio is >7: 1. Other histopathological features of FPHL show a reduction in hair 
follicle size, depth, and diameter of the hair shaft, with an increase in telogen: anagen 
ratio.10,13 Terminal hair has a diameter of more than 0.06 mm, whereas velus hair has a 
diameter of 0.03 mm or less and thinner.14 
 
Diagnosis  
The diagnosis of FPHL is made on the basis of the patient clinical condition (Figure 
5).1 Generally, FPHL is clinical diagnosis,2 there is no need for additional examination to 
establish a diagnosis of hair loss with a typical pattern. 
In anamnesis, some things that need to be asked to patients with suspected FPHL are 
the onset of age, duration, and progression of hair loss. Area of hair thinning usually occurs in 
the frontal, parietal, vertex, but can occur diffuse thinning. Family history of baldness is often 
be positive. Other things that need to be exclude as a cause of hair loss are medical conditions 
within 1 year before hair loss and history of other drugs/medication, such as iron deficiency, 
infections, thyroid disorders, strict diet, chemotherapy drugs, proandrogen hormones, anti-
thyroid.1,2 To get rid of presence of signs of hormonal dysregulation in polycystic ovarian 
syndrome (PCOS), fertility, amenorrhoea, irregular menstrual cycles, abortion, hyperandrogen 
signs (excessive hair growth, acne) need to be examined.10,12 
On physical examination, scalp and hair are examined, as well as whole body hair on 
women with hair loss complaints. Examination of the whole body's hair to identify the signs 
of hyperandrogenism, such as, excessive terminal hair in the body, acne, seborrheic, and 
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obesity.9,10 In FPHL, normal scalp is found, no cicatric, terminal hair loss, variations in hair 
size, and miniaturization of hair.12  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The hair expert consensus proposed an assessment to diagnose and quantify female 
pattern hair loss using The ‘Female Pattern Hair Loss Severity Index (FPHL-SI) to assess the 
severity scale with a value of 0-20 (Table 1). The severity index of FPHL is assessed through 
hair loss (visual shedding scale (Figure 6) and hair pull test), center hair density (Sinclair 
scale), and trichoscopy. A value of 0-4 indicates not a diagnosis of FPHL, 5-9 indicates an 
early stage of FPHL, and a higher value indicates an advanced severity.15 
 
 
Female  
Androgenetic Alopesia 
 
Suspect 
hyperandrogen, 
refer to an 
endocrine 
specialist 
Check hormones 
Check for signs of hormone dysregulation 
(menstrual cycle, body hair examination, acne, seborrheic) 
Normal Pathological  
Normal 
 
Pathological 
 
M
al
e 
Male 
Yes 
Negative 
Pattern 
classification 
Hair Pull 
test 
Check DD  
Active hair loss 
Yes Distribution 
pattern? 
Hair loss 
No There is no 
suspicion of the 
AGA, Check DD  
 
 Positive  
Check DD Seborrheic dermatitis 
There is no hair loss 
Scalp condition 
Pathological 
Other scalp 
disease 
AGA suspect 
Normal  
Female  
Fe male 
Female  
Figure 5. Diagnosis algorithm of hair loss pattern.11 
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Figure 6. Visual shedding scale.6 
Table 1. FPHL-SI assessment sheet (maximum score of 20)15 
FPHL-SI 
diagnostic 
criteria 
 FPHL-SI score 
 0 1 2 3 4 5 6 8 10 
Increased hair 
loss: 
Shedding scale/ 
hair pull test 
The Sinclair 
Scale 1-
4/negative 
pull test  
0 
 The Sinclair 
scale 5/6 / 
positive pull 
test 
2 
      
Midline Hair 
Density: 
Sinclair hair 
density scale 
Sinclair 1 (NH 
I-II) 
0 
   Sinclair 
2 
(NH III) 
4 
Sinclair 
3 
(NH IV) 
6 
Sinclair 
4 
(NH IV) 
6 
Sinclair 
5 
(NH V) 
8 
Sinclair 
6 
(NH VI-
VII) 
10 
Trichoscopy: 
(A) Difference in 
hair diameter 
<20% hair 
0 
    >20% 
hair 
5 
   
Trichoscopy: 
(B) Three / one 
hair per 
follicular unit 
(FU) There is 
no difference 
between the 
frontal and 
occipital 
areas 
Tidak ada 
perbedaan 
antara area 
frontal dan 
oksipital 
0 
≥25% one 
hair / FU or 
≥25% 
reduction in 
three hairs / 
FU between 
frontal and 
occipital 
1 
≥50% one 
FU hair 
2 
 
≥75% 
one FU 
hair 
3 
     
Total FPHL-SI 
score (0-20). 
 
0-4 is not FPHL 
5-9 initial FPHL 
≥ 10 FPHL 
         
                                                                                                          
     ISSN 2598 0580  
 
 Bioscientia Medicina Page 37 
 
 
Management 
The goal of FPHL management is to stop progressive hair loss and stimulate hair 
growth.1 Early management and combination terapi would give good result. To date, FDA-
approved FPHL therapies include 2% minoxidil topically, surgical therapy, and low-level 
laser therapy (LLLT).2 Other alternative therapies that may be effective, but require further 
research, such as hormonal therapy, microneedling, and PRP.16 The FPHL therapy algorithm 
is adjusted to the severity according to Ludwig's criteria.2 In general, FPHL therapy is 
classified into pharmacological (topical and systemic) therapy, hair transplantation and laser, 
aesthetic (wig, hair extension, camouflage), and alternative therapies that need further 
investigations.1,2,16 (Figure 7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Ludwig III  Ludwig I-II 
Endocrine Examination Topical minoxidil for 1 year 
Hair piece and / or 
- Antiandrogens / finasteride 
- Low fluence laser light 
Improvement / stabilization 
YES NO 
Continue 
topical 
minoxidil 
Hair piece and / or 
- Antiandrogens / finasteride 
- - Low fluence laser light 
Hair transplantation and / or 
- Antiandrogens / finasteride 
- Low fluence laser light 
Occipital donor area 
Algorithm for FPHL therapy 
NO YES 
Figure 7. FPHL management algorithm2 
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Pharmacological Therapy 
Topical minoxidil 
Minoxidil is an antihypertensive derivative of piperidinopyrimidine which orally 
causes vasodilation and hypertrichosis. In topical use, minoxidil increases terminal hair 
density. Minoxidil does not have anti-androgen effects but increases follicular proliferation 
directly, produces anagen hair, and increases the size of hair follicles.1,2 
Minoxidil exerts an effect when converted to a form of active metabolite, minoxidil 
sulfate, by the enzyme sulfotransferase in the outer hair roots of anagen follicles. The exact 
mechanism of minoxidil can accelerate hair growth is still unclear. Minoxidil sulfate opens 
the ATP-potassium pathway in the cell membrane, thus giving a vasodilating effect, but this 
vasodilating effect has no effect on hair growth. Minoxidil effects that might affect hair 
growth include:16 
1.  Increased expression of vascular endothelial growth factor (VEGF) mRNA in papilla 
dermis causing angiogenesis in papilla dermis. 
2.  Activation of cytoprotective prostaglandin synthase-1, a cytoprotective enzyme that 
stimulates hair growth. 
3.  Increased expression of hepatocyte growth factor (HGF) mRNA which is a hair 
growth promoter 
Topical minoxidil is available in 2% and 5% solutions and 5% foam. Minoxidil used 
for FPHL therapy is 2% solution. Topical minoxidil solutions are given to the scalp in dry 
conditions twice daily for 1 ml each application for at least 6 months. Minoxidil solution or 
foam is maintained at least 4 hours before the next shampoo. This therapy is a long-term 
therapy and takes 4-6 months before the drug starts working and the maximum effect is 
expected to occur after 1 year. Patients need to be informed that in the first 8 weeks of use of 
topical minoxidil, hair loss can still happen.2,12,16 
Minoxidil contains propylenglycol which can give side effects such as local irritation, 
hypertrichosis, and contact dermatitis. This can be reduced by the use of a 2% concentration 
solution and the type of foam that contains less of that material.2,6 The effectiveness of 
minoxidil in FPHL shows a level of evidence 1.16 
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Hormonal therapy 
The process of androgen conversion and binding with androgen receptors are targeted 
in hormonal therapy in FPHL. Included in FPHL hormonal therapy are 5-α-reductase and 
anti-androgen inhibitors.16,17  
 
5-α-reductase inhibitors 
In the human body there are 2 types of 5-α-reductase inhibitors. Type I is dominant in 
the liver, skin, and scalp while type II is dominant in the prostate and genitourinary tract 
fractures, and hair follicles.6 Initially, 5-α-reductase inhibitors were used for the treatment of 
benign prostatic hyperplasia (BPH). Finasteride and dutasteride are 2 drugs that inhibit the 
action of the 5-α-reductase enzyme. The 5-α-reductase enzyme is the target of treatment in 
FPHL because it plays a role in the process of converting testosterone to a stronger form of 
androgen, DHT which has the ability to bind to androgen receptors 5 times greater than 
testosterone.2,16 
Finasteride, a synthetic steroid-azo, is very potent and sensitive to type 2-α-reductase 
inhibitors. It binds to 5-α-reductase isoenzymes and prevents the conversion of testosterone to 
DHT.2,6 Finasteride 1mg daily can reduce DHT concentration in scalp by 64%, and in serum 
as much as 68%.7 Finasteride has not been accepted for the treatment of FPHL and its 
effectiveness in FPHL is still controversial. In postmenopausal FPHL women, the use of 
finasteride 1 mg daily did not show a significant effectiveness of anagen: telogen and terminal 
hair: velus ratio (level of evidence 2).16 Further research is needed for higher doses in a group 
of female patients with FPHL. The use of finasteride in FPHL patients of childbearing-age 
requires a safe method of contraception because it has been shown to cause feminization in 
male fetuses. Another side effect is an increase in the hormone estrogen due to the effects of 
aromatase which converts testosterone to estradiol so that this therapy is not given to patients 
with a history of breast cancer in the patient or family.16,17 
Finasteride is quickly absorbed and reaches peak levels in plasma after 1-2 hours of 
consumption. The half-life of finasteride plasma is 6 hours. As many as 90% of the drug binds 
to plasma protein. Finasteride is metabolized in the liver by hydroxylation and oxidation of P-
450 via the 3A4 pathway without interaction with other drugs that are metabolized by 
cytochrome P-450 such as warfarin, theophylline, digoxin, and propranolol.16 
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Dutasteride is a type I and II-5-reductase inhibitor. When compared with finasteride, 
dutasteride has three times more potent in inhibiting type I 5-α-reductase and 100x more 
potent in inhibiting type 5-α-reductase. It has teratogenic effects and increase the risk of 
breast cancer. In male AGA, dutasteride is given at a dose of 0.5 mg daily, but FDA does not 
recommend for FPHL.16,17 
Anti androgen 
  Oral anti androgens for FPHL still need further investigations. There is no strong 
enough evidence to support the use of oral anti androgens to increase or prevent the 
progression of FPHL. Oral anti androgens that are currently being studied and used as 
alternative therapies on FPHL are spironolactone, cyproterone acetate, and flutamide (level of 
evidence 3)16 
Spironolactone is off-labeled for FPHL therapy at a dose of 100-200 mg daily for a 
minimum of 6 months.2 Spironolactone is a potassium-saving diuretic drug, aldosterone 
antagonist.1 Spironolactone acts as an anti-androgen by reducing the amount of testosterone 
and inhibiting androgen receptors in target tissue. This drug is commonly used to treat 
hirsutism related to PCOS. The use of spironolactone in women of childbearing-age requires 
contraception to reduce menorrhagia. Spironolactone side effects are postural hypotension, 
menorrhagia, lethargy, nausea, feminization in male fetuses, and hyperkalemia. 
Spironolactone is contraindicated in patients with renal insufficiency, hyperkalemia, 
pregnancy, abnormal uterine bleeding, woman with predisposition to breast cancer.16,17 
Cyproterone acetate is given at a dose of 50 mg daily on days 1-10 of the menstrual 
cycle and 35 micrograms of ethinyl estradiol on days 1-21 of the menstrual cycle or 100 mg 
of cyproterone acetate on days 5-15 of the menstrual cycle and 50 micrograms of ethinyl 
estradiol on days 5- 25 menstrual cycles.2 This drug directly block androgen receptors and 
decrease the amount of testosterone by suppressing follicle stimulating hormone (FSH) and 
luteinizing hormone (LH). Side effects of these drugs include mood disorders, liver toxicity 
feminization in male fetuses, menstrual cycle disorders, weight gain, depression, decreased 
libido, and nausea.3,16 
Flutamide is an anti androgen that inhibits androgen binding with androgen receptors. 
This drug is effective for the treatment of hirsutism and FPHL with hyperandrogens 
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Flutamide is given at a dose of 62.5 mg / day and promotes hair growth after 6 months of use 
and a long-term stable effect. The side effect of the drug is liver toxicity.3,16 
 
Non-pharmacological Therapy 
Low level laser therapy  
The LLLT device was first cleared for use in management of baldness and approved 
by the FDA in 2007.18,19 Until the end of 2014, the LLLT that was cleared for management of 
hair loss is HairMax LaserComb® (Lexington Internastional, Boca Raton, FL), He-Ne laser, 
MEP 90 stationary hood (Hartland Technologies), Theradome laser helmet (Theradome, Los 
Angeles, CA), and Apira iGrow laser helmet (Apira Science Inc., Boca Raton, FL). The  
HairMax LaserComb and Apira iGrow laser helmet are the only devices with published 
clinical findings in peer-reviewed journals.19 
The LLLT, a 650-900 nm infrared, can cause proliferation, migration, oxygenation, 
and adhesion as well as the transition from telogen to anagen. Cytochrome C oxidase (COO) 
absorbs infrared light resulting in the release of nitric oxide (NO) which binds O2, causing 
electron transport to produce ATP and reactive oxygen species (ROS) through respiration in 
the mitochondria. Another hypothesis states that LLLT activates COO as nitrate reductase, 
causing the release of NO from the intracellum resulting in vasodilation and accumulation of 
ROS and ATP resulting in cell proliferation, migration, oxygenation, and adhesion. LLLT 
rays increase the signal wingless family (Wnt) and extracellular receptor kinase (ERK) 
thereby increasing transcription factors including Lef1. Transcription factors produce gene 
expression and release of paracarin stimulation. Paracrine signals along with infrared light 
produce keratinocyte proliferation and transition to the anagen phase.17,19 
The LLLT that are FDA approved have a wavelength of 655 nm with 3 types of light 
7,9,12 beams. The optimal dose or therapeutic regimen for LLLT is unknown. Most LLLT 
devices are used 15-20 minutes, every day or 3 times / week for 26 weeks. Furthermore, 
maintenance therapy is continued 1 time / week for 6 months.18 The advantage of LLLT is no 
side effects and easy to use. Jimenez, et al (2014) showed that the use of HairMax 
LaserComb® at 128 MPHL and 141 FPHL can increase terminal hair density after 26 weeks 
of therapy.20 
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Hair Transplantation 
Hair transplantation is the treatment of choice for severe FPHL and is not successful 
with pharmacological therapy (level of evidence 4).16 This is contraindicated in patients with 
uncontrolled systemic diseases, such as hypertension, heart disease, and diabetes mellitus. The 
presence of local diseases such as cutaneous lupus erythematosus, morphea, alopecia areata, 
and scalp folliculitis should be treated at least 6 months before a hair transplant.21 Before the 
transplantation, the medical conditions, history of medications, family history of alopecia, 
realistic expectations of patients for surgical therapy, and donor area conditions should be 
consider. 22 
The gold standard for hair restoration surgical therapy is follicular unit transplant 
(FUT).21 Graft in FUT can be taken using strip harvest or folicullar unit extraction (FUE) 
technique. In the harvest strip technique, strips containing hair are excised from the donor 
region and cut under a microscope to FUT, the donor area is taken with a length of 18 cm and 
a width of 1 cm obtained 1800 follicular units (100 follicular U / cm2). In the FUE technique, 
FUT is extracted directly from the donor area by punch biopsy with a diameter of 0.8-1.2 mm 
so that it does not require stitches. The donor area taken is the occipital area.2,23 
 
Camouflage 
Camouflage is an options for hair baldness management include partial or full wigs, 
hair extensions, concealing powder and sprays, and tatto. Camouflage is the simplest, easiest, 
and cheapest way to manage androgenetic alopecia. Camouflage therapy can be done by scalp 
coloring. Color selection is similar to hair color, thus giving the illusion of thicker hair. 
Powder that is applied on the scalp to hide baldness is water resistant and can be remove with 
shampoo. After application, then the hair is brushed to distribute the powder evenly. In 
addition to powder, camouflage material can also be lotion and spray. The limitation of this 
camouflage material that requires daily use and water activities can distort the camuflage.14,24 
Some diffuse AGA patients prefer to use a wig. Wigs can be washed and styled and 
can cover baldness with natural-looking. Wigs can be made of real or synthetic hair. Wigs 
derived from real human hair can last 3-4 years, while synthetics wigs are replaced every 3-6 
months. The real human hair wig looks more natural, can be adjusted with low heat, cooler 
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when worn, can be colored, but it costs more, requires hair and care settings, is more prone to 
fading due to sunlight and the environment, heavier than a synthetic wig. While the synthetic 
wigs are easy maintenance, cheaper, lighter, less prone to fading due to sunlight. The 
synthetic wigs cannot be dyed, hotter when used, unnatural-looking, and more prone to heat 
damage.24 
Another hair camouflage material is hair extensions, usually made from animal hair 
such as horses and sheep. Hair extension is a strand of synthetic hair or hair that comes from 
humans and is attached to hair fibers using glue, braids, sewing or clips. Unfortunately, hair 
extensions can make alopecia worse due to traction.24 
 
Platelet Rich Plasma  
Platelet rich plasma is an autologous platelet concentration containing a small amount 
of plasma which can accelerate the rejuvenation of skin and hair follicles due to growth 
factors and cellular adhesion molecules. This new modality in alopecia therapy activate the 
stem cells in the hair bulb area and induce the expression of hair growth factors related to 
genes to restore the anagen hair-forming mediator. The PRP contains 20 types of growth 
factors such as platelet derived growth factor (PDGF) which stimulates the growth of the 
dermis mesenchyme, vascular endothelial growth factor (VEGF) which increases the hair 
follicle vascularization, epidermal growth factor (EGF) which increases growth towards the 
anagen phase and prevents growth of the anagen phase follicular regression, insulin-like 
growth factor 1 (IGF-1) which slows apoptosis, fibroblast growth factor (FGF) which 
increases growth towards the anagen phase, nerve growth factor (NGF) which stimulates hair 
growth and slows apoptosis. Platelet concentrations in PRP preparations 3-5 times higher than 
concentrations in blood.5,25 Administration of PRP into the skin perform through mesotherapy 
injection or microneedling methods.5  
Khatu, et al (2014) reported that 9 of 11 AGA patients treated with PRP showed 
negative hair pull test, increase hair volume and hair-covered areas of baldness after 4 
sessions of PRP.26 Greco, et al reported that there is a significant increase in hair density and 
diameter of AGA patients in the PRP group.27 Singhal, et al showed that in 10 AGA patients 
treated with PRP for 3 months, the pull test results were reduced by 65%. New hair growth 
was obtained in 6 patients in 10 days and 4 patients in 15 days.28 
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Although PRP is a simple, inexpensive, and applicable method for management of 
baldness and has enough theory to support hair restoration, however, the clinical evidence is 
still weak.29,30 The PRP is a safe procedure, complications that usually occur after the 
procedure are pain at the injection site, headache, swelling, redness, infection, and allergic 
reactions such as urticaria.26 
 
Microneedling 
Microneedling is a minimally invasive procedure, using multiple fine needles that are 
inserted into the stratum corneum. Microneedling produces micropuncture so that it 
accelerates the process of wound healing, followed by the release of PDGF, activation of stem 
cells in the hair bulb area, and induction of hair growth factors associated with genes namely 
VEGF, β-catenin, Wnt3a, and Wnt10b, forming collagen and neovascularization. 
Microneedling facilitates penetration of other hair growth promoting therapies, such as 
minoxidil, PRP, topical steroid to stimulate the growth of hair follicle.31 
Microneedling therapy can use a tubular roller surrounded by fine needles with a 
length between 0.5-2.5 mm which is rolled over the skin repeatedly in a vertical, horizontal, 
diagonal direction 15-20 times so as to produce 250 holes/cm2. Another device, dermapen, is 
inserted vertically on the scalp with certain speed and depth of penetration. Before procedure, 
topical anesthesia, a mixture of lignocaine and/or prilocaine/tetracaine needs to be applied and 
aseptic procedure is required. The final result of microneedling technique is erythema or 
bleeding spots. This technique is more effective if combined with PRP or minoxidil therapy 
24 hours after the procedure.31 Dhurat, et al. compare microneedling and 5% minoxidil twice 
daily versus 5% minoxidil alone in a pilot study, showed that mean change in hair count were 
statistically better in the microneedling plus minoxidil group after 12 weeks of treatment.32 
 
PROGNOSIS 
Early onset FPHL may lead to faster progression of hair loss. There is no therapy that 
can cure FPHL.13 This condition is progressive without therapy. However, the therapy 
provided can only slow the progression of hair loss by several years and stimulate partial hair 
growth. The response to therapy is generally slow and requires patience from patients and 
doctors. The cosmetic effects of FPHL also need to be considered so that in addition to 
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pharmacological therapy, cosmetic camouflage can also be considered and hair transplant 
surgical treatment can be an option for severe case.17 
This condiction has a social and psychological impact on patients. Treatment can only 
prevent the progression of hair loss and there is not cure of FPHL. 
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